Intriguingly, mounting evidence indicated that breast cancers with BRCA1 mutation were more likely to exhibit triple-negative phenotype compared with the BRCA1 noncarriers [18, 20, 40–44, 49], which showed that BRCA1 could play a unique role in the progression of TNBCs. The gene discussed is BRCA1; the disease is breast cancer.